ALFERON N INJECTION
LOE Approachinginterferon alfa-n3
BLAVIAL
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALFERON N INJECTION (Interferon Alfa-N3) is a biologic interferon product approved in 1989 for HIV infection treatment. It is a naturally derived interferon with immunomodulatory properties. The drug represents an older class of HIV therapy now largely superseded by modern antiretrovirals.
LOE Approaching
Declining
Minimal commercial momentum; supporting a legacy product with shrinking patient population and budget allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
HIV Infections
Career Relevance
Working on ALFERON N offers minimal career growth trajectory; the product is in managed decline with shrinking commercial relevance and zero linked job openings. Professionals on this team should prioritize transition to growth-stage products or newer indication areas within their organization.
Product Manager (Legacy/Transition)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.